March 1, 2022:
Manish Patel, DO and Naomi Fujioka, MD from the Masonic Cancer Center at the University of Minnesota were recently appointed as co-chairs of the Big Ten Cancer Research Consortium’s Head and Neck Clinical Trial Working Group. Read More
February 24, 2022: Just over 50 years ago, President Richard Nixon signed the National Cancer Act – more commonly known as the “War on Cancer.” While harnessing the resources of the federal government was an important step forward, many have commented (including current NCI director Dr. Ned Sharpless) the effort was simultaneously ambitious and naïve. Naïve in the sense that we did not yet understand our enemy. About 25 years into the “war,” the New England Journal of Medicine published an article entitled, “Cancer Undefeated” wherein declining death rates were attributed to changing incidence rates and early detection practices (Bailar, et al. N Engl J Med 336:1569 1997 PMID: 9164814), not because of advances in therapy. Read More
February 23, 2022: This month, the Big Ten Cancer Research Consortium highlights the Masonic Cancer Center at the University of Minnesota and physician-scientist Emil Lou, MD, PhD, FACP. Investigator Spotlight: Emil Lou, MD, PhD, FACP (@cancerassassin1), Associate Professor in the Department of Medicine, Division of Hematology, Oncology and Transplantation, Department of Medicine and Graduate Faculty Program member in the Integrative Biology and Physiology Program (IBP) at the University of Minnesota; and Medical Director of the UMN Masonic Cancer Center’s Clinical Trials Office (CTO)-Solid Tumor Unit.
February 18, 2022: Big Ten Cancer Research Consortium investigators presented a Trial in Progress abstract at the 2022 American Society of Clinical Oncology Genitourinary Cancer Symposium. The abstract titled, A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer, is led by David J VanderWeele, MD, PhD of the Robert H Lurie Comprehensive Cancer Center of Northwestern University. Read More
February 14, 2022: Big Ten Cancer Research Consortium Investigators recently presented abstracts during the 2022 Gastrointestinal Cancers Symposium. The abstracts included a poster featuring the BTCRC-GI15-015 study, led by Al B. Benson III, MD of Robert H Lurie Comprehensive Cancer Center of Northwestern University, and a trials in progress poster featuring BTCRC-GI20-457 led by Kristen Renee Spencer, DO, MPH of Rutgers Cancer Institute. Read More
February 12, 2022: Big Ten Cancer Research Consortium (Big Ten CRC) investigators recently published results of clinical trial BTCRC-ESO14-012 in the notable Frontiers in Oncology journal. The publication titled, A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study, found adjuvant durvalumab in patients with residual disease in the surgical specimen following trimodality therapy (a combination of chemotherapy, radiation, and surgery) for locally advanced...
February 11, 2022: Big Ten Cancer Research Consortium investigators presented a trial in progress abstract at the 2021 San Antonio Breast Cancer Symposium. The abstract titled, A Phase II Study of Pembrolizumab plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients, was presented by Nancy Chan, MD of Rutgers Cancer Institute of New Jersey. Read More
January 28, 2022: The Big Ten Cancer Research Consortium (Big Ten CRC) honored member institution, University of Wisconsin Carbone Cancer Center and George Weiner, MD (pictured left), of the Holden Comprehensive Cancer Center, University of Iowa on Wednesday, January 26, during the monthly Big Ten CRC Grand Rounds meeting. Read More
December 7, 2021: This month, the Big Ten Cancer Research Consortium highlights UW Carbone Cancer Center and Jeremy Kratz, MD, a medical oncologist and researcher at the cancer center. Dr. Kratz is a member of the Big Ten CRC's Gastrointestinal Clinical Trial Working Group. For Dr. Kratz, pushing cancer care and research forward is much more than an academic pursuit. It’s personal. Read More
November 7, 2021: This month, the Big Ten Cancer Research Consortium features our member institution University of Iowa Holden Comprehensive Cancer Center and medical oncologist Margaret Byrne, MD, MS, clinical assistant professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation at the Carver College of Medicine. Dr. Byrne’s research interests include early-phase clinical trials of adjunctive therapies to enhance the efficacy of immune checkpoint inhibitors in patients with head, neck, and lung cancers. Her clinical expertise includes thoracic malignancies and head and neck cancer.
University of Illinois
Indiana University
University of Iowa
University of Maryland
University of Michigan
Michigan State
University of Minnesota
University of Nebraska
Northwestern University
Penn State University
Purdue University
Rutgers State University
University of Wisconsin
University of Illinois at Chicago
© 2024 All rights reserved.
Big Ten Cancer Research Consortium
7676 Interactive Way, Suite 120, Indianapolis, IN 46278
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube